A Phase 4 interventional study of Ticagrelor and Clopidogrel in Non-ST or ST Elevation Acute Coronary Syndromes, sponsored by AstraZeneca. Completed at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-15.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 47th largest by enrollment, is one of 8 that started in 2013, is one of 38 in phase 4, and was the 14th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Ireland, Latvia, Norway and 2 more countries
Ages 18+
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Medical University of Gdansk · Sites in Poland
Ages 18+
Fu Wai Hospital, Beijing, China · Sites in China
Ages 18+
Shanghai Tong Ren Hospital · Sites in China
Ages 75+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 38
First in 2006; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 200 across 867 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 120 across the 67 interventional studies. Of the 45 that completed or were terminated, 13 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 67 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
36 studies in Acute Coronary Syndrome by AstraZeneca: none open now, none under way, none of them phase 3. Of 35 finished, 8 (23%) have results posted.
Among the 36 studies in Acute Coronary Syndrome by AstraZeneca, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2013, is one of 5 in phase 4, and was the 18th registered.
AstraZeneca’s Acute Coronary Syndrome studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 36 in Acute Coronary Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ticagrelor
Drug: Clopidogrel
90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
the Percentage Inhibition of the P2Y12 Receptor
Note: the primary endpoint was changed per the statistical analysis plan prior database lock.
Time frame: at 2 hours after first dose of study drug
the Percentage Inhibition of the P2Y12 Receptor
Time frame: at 0.5 hour after first dose of study drug
the Percentage Inhibition of the P2Y12 Receptor
Time frame: at 8 hours after first dose of study drug
the Percentage Inhibition of the P2Y12 Receptor
Time frame: at 24 hours after first dose of study drug
the Percentage Inhibition of the P2Y12 Receptor
Time frame: at 6 weeks after first dose of study drug
First subject enrolled: 15/05/2013, Last subject last visit: 18/03/2014. There were 5 study centers in China, which participated this study.
| Milestone | Ticagrelor | Clopidogrel |
|---|---|---|
| Started | 29 | 31 |
| Completed | 26 | 25 |
| Not completed | 3 | 6 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Incorrect enrolment | 1 | 0 |
| Withdrew: Disease need | 1 | 1 |
| Withdrew: Need gp iib/iiia | 1 | 3 |
Note: the primary endpoint was changed per the statistical analysis plan prior database lock.
| Percentage Inhibition | Ticagrelor | Clopidogrel |
|---|---|---|
| the Percentage Inhibition of the P2Y12 Receptor | 48.20 ± 45.410 | 9.78 ± 27.574 |
| Percentage Inhibition | Ticagrelor | Clopidogrel |
|---|---|---|
| the Percentage Inhibition of the P2Y12 Receptor | 8.23 ± 25.810 | -3.91 ± 13.602 |
| Percentage Inhibition | Ticagrelor | Clopidogrel |
|---|---|---|
| the Percentage Inhibition of the P2Y12 Receptor | 67.91 ± 34.856 | 25.38 ± 32.738 |
| Percentage Inhibition | Ticagrelor | Clopidogrel |
|---|---|---|
| the Percentage Inhibition of the P2Y12 Receptor | 79.25 ± 17.920 | 28.76 ± 26.917 |
| Percentage Inhibition | Ticagrelor | Clopidogrel |
|---|---|---|
| the Percentage Inhibition of the P2Y12 Receptor | 83.78 ± 13.947 | 24.22 ± 33.546 |
Collected over 6 weeks for all AEs and another 14 days for SAEs.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticagrelor | — | 1/29 (3.4%) | 12/29 (41.4%) |
| Clopidogrel | — | 1/31 (3.2%) | 12/31 (38.7%) |
| Event | Ticagrelor | Clopidogrel |
|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/29 | 0/31 |
| Drug-induced liver injuryInjury, poisoning and procedural complications | 0/29 | 1/31 |
| Event | Ticagrelor | Clopidogrel |
|---|---|---|
| Hypertensive heart diseaseCardiac disorders | 3/29 | 2/31 |
| HyperuricaemiaMetabolism and nutrition disorders | 3/29 | 2/31 |
| Hepatic function abnormalHepatobiliary disorders | 2/29 | 3/31 |
| HyperlipidaemiaMetabolism and nutrition disorders | 2/29 | 1/31 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 2/29 | 0/31 |
| Back painMusculoskeletal and connective tissue disorders | 2/29 | 0/31 |
| ArrhythmiaCardiac disorders | 0/29 | 2/31 |
| Lung infectionInfections and infestations | 1/29 | 0/31 |
| PharyngitisInfections and infestations | 1/29 | 0/31 |
| Upper respiratory tract infectionInfections and infestations | 1/29 | 0/31 |
Three randomized patients were excluded from the full analysis set (FAS) due to any of the following reasons: 1) did not meet exclusion requirments but was randomized, 2)post-treatment blood PRU was not available, 3) pre-treatment blood PRU was missing, and 4) use of prohibited medications.
| Age, Continuous(years) | Ticagrelor | Clopidogrel | Total |
|---|---|---|---|
| Mean | 58.75 ± 10.967 | 58.59 ± 9.789 | 58.67 ± 10.291 |
| Sex: Female, Male(Participants) | Ticagrelor | Clopidogrel | Total |
|---|---|---|---|
| Female | 2 | 8 | 10 |
| Male | 26 | 21 | 47 |
| Race (NIH/OMB)(Participants) | Ticagrelor | Clopidogrel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 28 | 29 | 57 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of May 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor